apm global face recognition terminal with thermal scanner
apm global pte ltd - general hospital - apm face recognition terminal with thermal scanner (apm-fr001-t) is a kind of access control device( facial recognition) integrate with temperature measuring function.this device is intended to be used indoors only.
tabrecta film-coated tablet 150mg
novartis (singapore) pte ltd - capmatinib dihydrochloride monohydrate eqv capmatinib - tablet, film coated - capmatinib dihydrochloride monohydrate eqv capmatinib 150mg
tabrecta film-coated tablet 200mg
novartis (singapore) pte ltd - capmatinib dihydrochloride monohydrate eqv capmatinib - tablet, film coated - capmatinib dihydrochloride monohydrate eqv capmatinib 200mg
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
gopten 0,5 mg sert kapsul, 20 adet
abbott laboratuarlari İthalat İhracat ve tİc. ltd. Ştİ. - trandolapril - trandolapril
tabrecta 150 mg
novartis israel ltd - capmatinib as dihydrochloride monohydrate - film coated tablets - capmatinib as dihydrochloride monohydrate 150 mg - capmatinib - tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an approved test.
tabrecta 200 mg
novartis israel ltd - capmatinib as dihydrochloride monohydrate - film coated tablets - capmatinib as dihydrochloride monohydrate 200 mg - capmatinib - tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an approved test.
tabrecta
predstavniŠtvo novartis pharma services inc. beograd (novi beograd) - kapmatinib -
tabrecta
predstavniŠtvo novartis pharma services inc. beograd (novi beograd) - kapmatinib -